T-0156

• Description:

  T-0156 is a potent and selective phosphodiesterase type 5 (PDE5) inhibitor. T-0156 specifically inhibits the hydrolysis of cyclic guanosine monophosphate (cGMP) by PDE5 in a competitive manner (IC50=0.23 nM) . T-0156 inhibits PDE6 (IC50=56 nM) and has low potencies against PDE1, PDE2, PDE3, and PDE4 (IC50>10 μM) . T-0156 enhances the nitric oxide (NO) /cGMP pathway[1].

• UNSPSC:

  12352005

• Target:

  Phosphodiesterase (PDE)

• Type:

  Reference compound

• Related Pathways:

  Metabolic Enzyme/Protease

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/t-0156.html

• Solubility:

  10 mM in DMSO

• Smiles:

  COC (C (N1CC2=CC=NC (C) =C2) =C (C3=CC (OC) =C (OC) C (OC) =C3) C4=CC=NC (OCC5=NC=CC=N5) =C4C1=O) =O.Cl

• Molecular Formula:

  C31H30ClN5O7

• Molecular Weight:

  620.05

• References & Citations:

  [1]Hideki Mochida, et al. Enzymological and pharmacological profile of T-0156, a potent and selective phosphodiesterase type 5 inhibitor. Eur J Pharmacol. 2002 Dec 5;456 (1-3) :91-8.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  PDE1; PDE2; PDE3; PDE4; PDE5; PDE6

• CAS Number:

  324572-93-2